|
- Emend: Uses, Dosage Side Effects - Drugs. com
Emend is used together with other medications to prevent nausea and vomiting that may be caused by chemotherapy Emend is given ahead of time and will not treat nausea or vomiting that you already have
- Aprepitant - Wikipedia
Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting and to prevent postoperative nausea and vomiting [5]
- EMEND (fosaprepitant dimeglumine) for injection Label
Use of EMEND with strong or moderate CYP3A4 inhibitors (e g , ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions
- emend_pi - Merck
Oral administration of EMEND in combination with ondansetron and dexamethasone (EMEND regimen) has been shown to prevent acute and delayed nausea and vomiting associated with HEC including high-dose cisplatin, and nausea and vomiting associated with MEC
- Emend (Aprepitant): Uses, Side Effects, Dosage More - GoodRx
Emend (aprepitant) is a medication that's used to prevent nausea and vomiting caused by certain anti-cancer medications (chemotherapy) It's usually given an hour before your chemotherapy treatment on days 1 through 3
- Fosaprepitant (Emend injection, Focinvez): Uses, Side Effects . . . - WebMD
Overview: Fosarepitant is used to prevent nausea and vomiting Common side effects include tiredness, diarrhea, or weakness Fosaprepitant is given by a health care provider as an infusion into a
- Emend Capsules (Aprepitant Capsules): Side Effects, Uses . . . - RxList
Oral administration of EMEND in combination with ondansetron and dexamethasone (EMEND regimen) has been shown to prevent acute and delayed nausea and vomiting associated with HEC including high-dose cisplatin, and nausea and vomiting associated with MEC
- Emend: Package Insert Prescribing Information MOA
Emend package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
|
|
|